Extended from the standard K2EDTA tube, the cobas® EGFR Mutation Test v2 (CE-IVD) is now approved for use with the Roche Cell-Free DNA Collection Tube (CE-IVD) for plasma sample types. This offers enhanced flexibility in the transport and storage of collected blood prior to plasma separation, and facilitates the use of liquid biopsy for non-small cell lung cancer (NSCLC) patients needing molecular testing.
Up to 30% of advanced NSCLC patients do not have enough tissue specimen available for molecular analysis1, and ~15-18% of patients report clinical complications associated with tissue biopsy2. Liquid biopsy testing with the cobas® EGFR Mutation Test v2 provides healthcare professionals a clinically validated, non-invasive alternative for patients who may not be healthy enough for a tissue biopsy.